Opportunity Information: Apply for RFA IP 16 003
Apply for RFA IP 16 003
- The HHS-CDC-HHSCDCERA in the health sector is offering a public funding opportunity titled "Research on the Epidemiology, Prevention, Vaccine Effectiveness and Treatment of Influenza and Other Respiratory Viruses in South Africa" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.083, 93.283.
- This funding opportunity was created on Nov 09, 2015 and posted on Nov 09, 2015.
- Applicants must submit their applications by Jan 15, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $5,000,000.00 in funding.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This grant opportunity (RFA IP 16 003) is a CDC-funded cooperative agreement aimed at strengthening and expanding influenza and other respiratory virus research in South Africa through a formal collaboration between the CDCs National Center for Immunization and Respiratory Diseases (NCIRD), Influenza Division, and South Africas National Institute for Communicable Diseases (NICD). The core purpose is to generate stronger evidence on how influenza and other high-priority respiratory viruses spread, who they affect most severely, and how well prevention and treatment tools work in real-world South African settings. The work is framed around major public health questions such as the epidemiology and transmission of respiratory viruses, the overall disease burden they cause, the factors that increase the risk of hospitalization and severe outcomes, and the effectiveness of influenza vaccination and antiviral treatment.
A major reason this opportunity exists is that South Africa already has an unusually strong foundation for influenza surveillance and virus characterization through the long-running Viral Watch Programme, which has been collecting nationally representative information on influenza circulation for nearly 25 years. That program is also described as an important global contributor of influenza viruses used to help determine the composition of the Southern Hemisphere seasonal influenza vaccine. After the 2009 influenza pandemic, South Africa further expanded its surveillance in collaboration with the CDC to include monitoring of respiratory hospitalizations in five of the countrys nine provinces. While that platform has improved understanding of certain risk factors for severe disease, it has not produced enough data in key policy-relevant areas, especially estimates of influenza burden and vaccine effectiveness in populations specifically targeted for vaccination.
The cooperative agreement is designed to fill those gaps, with particular emphasis on groups where evidence is still limited, including pregnant women and their young infants. In practical terms, the award would support studies that move beyond describing virus circulation to quantifying outcomes such as hospitalizations and severe disease, identifying which underlying conditions or demographic factors are most associated with being hospitalized, and evaluating how well vaccination and antivirals reduce illness and serious complications. The intent is not only to maintain surveillance, but to expand collaborative research that can directly inform national vaccination strategies, maternal and infant protection approaches, and clinical and public health decisions about antiviral use.
Administratively, this opportunity is a discretionary award using a cooperative agreement mechanism, meaning the CDC expects to have substantial involvement with the recipient during the project period rather than acting solely as a funder. The opportunity lists an anticipated single award, with an award ceiling of $5,000,000. It was posted on November 9, 2015, created the same day, and had an application closing date of January 15, 2016. The sponsoring agency is HHS-CDC (HHSCDCERA), and the funding is associated with CFDA numbers 93.083 and 93.283. Eligibility is noted as "Others (see text field entitled Additional Information on Eligibility for clarification)," but the narrative makes clear that the collaboration is intended to be initiated with NICD in the Republic of South Africa as the primary partner organization for implementing the work.
Frequently Asked Questions (FAQs)
What is grant opportunity RFA IP 16 003?
RFA IP 16 003 is a CDC-funded cooperative agreement focused on strengthening and expanding influenza and other respiratory virus research in South Africa through a formal collaboration between the CDC (National Center for Immunization and Respiratory Diseases, Influenza Division) and South Africa's National Institute for Communicable Diseases (NICD).
Who is the sponsoring agency for this opportunity?
The sponsoring agency is HHS-CDC (HHSCDCERA).
What type of funding mechanism is used?
This is a discretionary award using a cooperative agreement mechanism, which means the CDC expects substantial involvement with the recipient during the project period (not just a hands-off funder role).
How many awards are anticipated?
The opportunity lists an anticipated single award.
What is the maximum award amount?
The award ceiling is $5,000,000.
What are the CFDA numbers associated with this funding?
The funding is associated with CFDA numbers 93.083 and 93.283.
What is the main purpose of this cooperative agreement?
The core purpose is to generate stronger evidence in real-world South African settings on how influenza and other high-priority respiratory viruses spread, who experiences the most severe outcomes, and how well prevention and treatment tools work.
What public health questions does the work aim to address?
The work is framed around major questions including the epidemiology and transmission of respiratory viruses, the disease burden they cause, factors that increase the risk of hospitalization and severe outcomes, and the effectiveness of influenza vaccination and antiviral treatment.
Why is this opportunity focused on South Africa?
South Africa has a strong foundation for influenza surveillance and virus characterization, including the long-running Viral Watch Programme, which has collected nationally representative information on influenza circulation for nearly 25 years.
What is the Viral Watch Programme and why is it important here?
The Viral Watch Programme is a long-running South African influenza surveillance system described as nationally representative and operating for nearly 25 years. It is also described as an important global contributor of influenza viruses used to help determine the composition of the Southern Hemisphere seasonal influenza vaccine.
How did South Africa's surveillance expand after the 2009 influenza pandemic?
After the 2009 pandemic, South Africa expanded surveillance in collaboration with the CDC to include monitoring of respiratory hospitalizations in five of the country's nine provinces.
What gaps is this cooperative agreement intended to fill?
It is intended to address gaps in key policy-relevant areas, especially estimates of influenza burden and vaccine effectiveness in populations specifically targeted for vaccination.
Does the opportunity focus only on surveillance?
No. The intent is not only to maintain surveillance, but to expand collaborative research that moves beyond describing virus circulation to quantifying outcomes such as hospitalizations and severe disease, identifying risk factors for hospitalization, and evaluating how well vaccination and antivirals reduce illness and serious complications.
Which populations are specifically emphasized?
The cooperative agreement places particular emphasis on groups where evidence is still limited, including pregnant women and their young infants.
What kinds of outcomes are expected to be quantified?
The supported studies are described as moving toward quantifying outcomes such as hospitalizations and severe disease, rather than only tracking virus circulation.
What types of risk factors are expected to be examined?
The work includes identifying which underlying conditions or demographic factors are most associated with being hospitalized and experiencing severe outcomes.
What does the opportunity say about evaluating prevention tools?
It includes evaluating the effectiveness of influenza vaccination in real-world South African settings, including in populations targeted for vaccination.
What does the opportunity say about evaluating treatment tools?
It includes evaluating how well antiviral treatment reduces illness and serious complications, with the intent of informing clinical and public health decisions about antiviral use.
How is this work expected to inform policy or programs?
The intent is to generate evidence that can directly inform national vaccination strategies, maternal and infant protection approaches, and decisions about antiviral use.
What does "substantial CDC involvement" mean in this context?
Because it is a cooperative agreement, the CDC expects to be substantially involved with the recipient during the project period, rather than acting solely as a funder.
Who is eligible to apply?
Eligibility is noted as "Others (see text field entitled Additional Information on Eligibility for clarification)." The narrative indicates the collaboration is intended to be initiated with NICD in the Republic of South Africa as the primary partner organization for implementing the work.
Which organizations are named as the key collaborators?
The named collaborators are the CDC's National Center for Immunization and Respiratory Diseases (NCIRD), Influenza Division, and South Africa's National Institute for Communicable Diseases (NICD).
When was the opportunity posted?
It was posted on November 9, 2015 (and created the same day).
What was the application closing date?
The application closing date was January 15, 2016.
What respiratory threats are included besides influenza?
The opportunity includes influenza and "other high-priority respiratory viruses" and aims to strengthen research related to influenza and other respiratory viruses in South Africa.
Is this opportunity connected to vaccine strain selection for the Southern Hemisphere?
Indirectly, yes. The information notes that South Africa's Viral Watch Programme is an important global contributor of influenza viruses used to help determine the composition of the Southern Hemisphere seasonal influenza vaccine.
Browse more opportunities from the same agency: HHS-CDC-HHSCDCERA
Browse more opportunities from the same category: Health
Next opportunity: Statistical Support for Inventory and Monitoring Projects
Previous opportunity: Sustainable Higher Education Research Alliances (SHERA)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA IP 16 003
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA IP 16 003) also looked into and applied for these:
| Funding Opportunity |
|---|
| SUPPORTING THE GHANA HEALTH SERVICE (GHS) IN THE STRENGTHENING OF NATIONAL HEALTH MANAGEMENT SYSTEMS IN THE AREAS OF STRATEGIC INFORMATION SYSTEMS, BLOOD SAFETY, AND LABORATORY CAPACITY BUILDING UNDER THE PRESIDENT’S EMERGENCY PLAN FOR AIDS RELIEF Apply for CDC RFA PS10 10440501SUPP16 Funding Number: CDC RFA PS10 10440501SUPP16 Agency: HHS-CDC Category: Health Funding Amount: $3,500,000 |
| Building Capacity for Human Resources for Health in HIV/AIDS in the Republic of Kenya under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH16 1624 Funding Number: CDC RFA GH16 1624 Agency: HHS-CDC-CGH Category: Health Funding Amount: $3,200,000 |
| Improving the Capacity of University Based Medical Education and Superior Training Institutions to Provide High Quality Education in the Republic of Mozambique Under the President's Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH11 1159SUPP Funding Number: CDC RFA GH11 1159SUPP Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Pre-application: Stimulating Peripheral Activity to Relieve Conditions (SPARC): Foundational Functional Mapping of Neuroanatomy and Neurobiology of Organs (OT1) Apply for RFA RM 15 019 Funding Number: RFA RM 15 019 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Strengthening the National Institutes of Health in the Republic of Mozambique under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH11 1158SUPP Funding Number: CDC RFA GH11 1158SUPP Agency: HHS-CDC Category: Health Funding Amount: $5,251,408 |
| NEI Clinical Study Planning Grant Program (R34) Apply for PA 16 038 Funding Number: PA 16 038 Agency: HHS-NIH11 Category: Health Funding Amount: $150,000 |
| Novel Nucleic Acid Sequencing Technology Development - Direct to Phase II (R44) Apply for RFA HG 15 039 Funding Number: RFA HG 15 039 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Applied Research Toward Zero Suicide Healthcare Systems (R01) Apply for RFA MH 16 800 Funding Number: RFA MH 16 800 Agency: HHS-NIH11 Category: Health Funding Amount: $600,000 |
| Comprehensive Community-Based HIV Prevention, Linkage, and Retention Services for Key Populations and Adolescent Girls and Young Women in the United Republic of Tanzania under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH16 1652 Funding Number: CDC RFA GH16 1652 Agency: HHS-CDC-CGH Category: Health Funding Amount: $630,000 |
| NHLBI Early Investigator Award (EIA) (R35) Apply for RFA HL 16 025 Funding Number: RFA HL 16 025 Agency: HHS-NIH11 Category: Health Funding Amount: $600,000 |
| Supporting Implementation of HIV and TB Services for Epidemic Control in the Republic of Mozambique under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH16 1632 Funding Number: CDC RFA GH16 1632 Agency: HHS-CDC-CGH Category: Health Funding Amount: $80,000,000 |
| Enhancing the Government of India’s Capacity to Scale Up and Improve Comprehensive HIV Service Package Quality for People Who Inject Drugs under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH15 154202CONT16 Funding Number: CDC RFA GH15 154202CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Flex Rural Veterans Health Access Program Apply for HRSA 16 015 Funding Number: HRSA 16 015 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Targeted Capacity Expansion-Peer-to-Peer (Short Title: TCE-PTP) Apply for TI 16 008 Funding Number: TI 16 008 Agency: HHS-SAMHS Category: Health Funding Amount: $250,000 |
| Implementing Comprehensive Community Based HIV/AIDS Prevention, Care and Treatment Services in Priority Areas in the Republic of Zambia under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH16 1668 Funding Number: CDC RFA GH16 1668 Agency: HHS-CDC-CGH Category: Health Funding Amount: $2,500,000 |
| Cooperative Agreements for Adolescent and Transitional Aged Youth Treatment Implementation [Youth Treatment – Implementation (Short Title –YT-I)] Apply for TI 16 006 Funding Number: TI 16 006 Agency: HHS-SAMHS Category: Health Funding Amount: $800,000 |
| Scholarships for Disadvantaged Students (SDS) Apply for HRSA 16 069 Funding Number: HRSA 16 069 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Early HIV Treatment to Optimize Patient Health and HIV Prevention Apply for RFA PS 16 006 Funding Number: RFA PS 16 006 Agency: HHS-CDC-HHSCDCERA Category: Health Funding Amount: $495,000 |
| Academic Units for Primary Care Training and Enhancement Apply for HRSA 16 041 Funding Number: HRSA 16 041 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Administrative Supplements for Complementary Health Practitioner Research Experience (Admin Supp) Apply for PA 16 013 Funding Number: PA 16 013 Agency: HHS-NIH11 Category: Health Funding Amount: $100,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA IP 16 003", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.